Daiichi Sankyo to Develop Thrombus Dissolving Agent

Article

Daiichi Sankyo signed an exclusive licensing agreement with clinical-stage biopharmaceutical company Translational Sciences to develop and commercialize its novel thrombus (blood clot) dissolving agent, TS23.

Daiichi Sankyo signed an exclusive licensing agreement with clinical-stage biopharmaceutical company Translational Sciences to develop and commercialize its novel thrombus (blood clot) dissolving agent, TS23, which is currently being studied in Phase I clinical trials.

“Daiichi Sankyo recognized the great potential of this novel therapy,” said Guy Reed, CSO/CEO of Translational Sciences, in a press release. “We believe they have the expertise and resources to fully develop it for the millions of patients each year who suffer cardiovascular disease and stroke. We are enormously grateful to the National Institutes of Health who provided crucial support to translate this research into therapy.”

Source:  Daiichi Sankyo 

Recent Videos
David Fairen-Jimenez
William K. Oh, MD
Eswar Iyer, Aikium Inc.
Leroy (Lee) Hood, MD, PhD
Behind the Headlines episode 5
Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.
Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.
Related Content
mainz,Rhineland-Palatinate /germany - 16 07 2022: the biontech company building and flags in mainz germany | Image Credit: © Tobias Arhelger - stock.adobe.com

BioNTech to Acquire CureVac in $1.25B Deal to Advance mRNA Cancer Therapies

Christopher Cole
June 12th 2025
Article

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer immunotherapies.

Kyiv, Ukraine - December 22, 2020: Backlit single shot image of GlaxoSmithKline logo on tv screen with a hand holding an Covid-19 vaccine concept. | Image Credit: © Олександр Луценко - stock.adobe.com

GSK Licenses Experimental Shigella Vaccine to Bharat Biotech for Global Health Deployment

Christopher Cole
June 12th 2025
Article

The partnership aims to accelerate late-stage development of a low-cost Shigella vaccine to combat child diarrhea and rising antimicrobial resistance.

Washington, DC, USA - June 24, 2022: The symbol of the U.S. Department of Health and Human Services is seen at the entrance to its headquarters in the Hubert H. Humphrey Building in Washington, DC | Image Credit: © Tada Images - stock.adobe.com.

Implications of RFK Jr.’s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry

Christopher Cole
June 10th 2025
Article

The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond.

A close-up of a vibrant blue and yellow eye with a DNA double helix, symbolizing genetics and vision science. | Image Credit: © Sonthana

ViGeneron Rebrands as VeonGen Therapeutics, Advancing Clinical-Stage Gene Therapies for Retinal Diseases

Christopher Cole
June 6th 2025
Article

The rebranding to VeonGen marks a strategic shift to clinical-stage development, reflecting progress from platform innovation to human trials in gene therapy.

mainz,Rhineland-Palatinate /germany - 16 07 2022: the biontech company building and flags in mainz germany | Image Credit: © Tobias Arhelger - stock.adobe.com

BioNTech to Receive Up to $11.1 Billion in Deal with BMS to Develop Immuno-Oncology Agent

Christopher Cole
June 2nd 2025
Article

BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, enters late-stage trials for lung and breast cancer with joint development by BioNTech and BMS.

An illustration of the glycan code showcasing the diversity of potential glycosylation patterns and their impact on protein function | Image Credit: © Justlight.

Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics

Christopher Cole
May 28th 2025
Article

Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.

© 2025 MJH Life Sciences

All rights reserved.